open access
Neuroendocrine neoplasms and somatostatin receptor subtypes expression
open access
Abstract
Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendocrine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indicate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type. Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs’ pharmacotherapy in patients with unsatisfactory course.
Abstract
Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendocrine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indicate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type. Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs’ pharmacotherapy in patients with unsatisfactory course.
Keywords
somatostatin, somatostatin receptor, SSTR, neuroendocrine neoplasm, NEN, expression
About this articleTitle
Neuroendocrine neoplasms and somatostatin receptor subtypes expression
Journal
Issue
Article type
Review paper
Pages
111-117
Published online
2016-07-29
Page views
4907
Article views/downloads
3881
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2016;19(2):111-117.
Keywords
somatostatin
somatostatin receptor
SSTR
neuroendocrine neoplasm
NEN
expression
Authors
Jerzy Hankus
Romana Tomaszewska
